Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.55 |
| ▸ | RARA | P10276 | 3/20 | 0.55 |
| ▸ | RARG | P13631 | 2/20 | 0.55 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609011 | 1.00 | RARB (0.55) | RARBRARARARGKMOKDM4E | |
| SCHEMBL30641680 | 0.94 | RARB (0.60) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL16534058 | 0.94 | RARB (0.60) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL17177744 | 0.89 | RARB (0.57) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL29372732 | 0.89 | RARB (0.57) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL6017915 | 0.86 | RARB (0.55) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL4652842 | 0.86 | RARB (0.58) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL31725051 | 0.86 | ACMSD (0.63) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL121429 | 0.86 | ACMSD (0.63) | RARBRARARARGKDM4ELMNA | |
| SCHEMBL5191893 | 0.85 | PPM1B (0.60) | RARBRARARARGKMOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | RARB 4092/4885RARA 4250/4885RARG 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.